Capstone Therapeutics Corp. (CAPS) outperforms the building products market as organic growth accelerates. Accelerating organic growth and market outperformance can lift near-term financial results and investor sentiment.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 0.05 | 0.01 | 0.73 | 0.23 |
| Receivables | 2.58 | 2.76 | 4.86 | 9.38 |
| Inventory | 13.75 | 9.64 | 17.06 | 16.39 |
| Other | — | — | — | — |
| 17.08 | 12.80 | 23.00 | 26.86 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 2.58 | 3.30 | 4.96 | 6.81 |
| ST’ Debt | 12.19 | 8.11 | 14.02 | 16.86 |
| Other | — | — | 1.40 | 0.70 |
| 15.97 | 12.55 | 22.92 | 27.11 |
| 10y | 5y | 3y | |
| Sales | — | — | ‡‡‡‡‡ |
| Cash Flow | — | ‡‡‡ | ‡‡‡ |
| Earnings | — | ‡‡‡ | ‡‡‡ |
| Book Value | — | ‡‡‡ | ‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 12.64 | 21.48 | — | — |
—
|
| ’25 | 7.90 | 12.85 | 13.65 | 12.48 |
46.88
|
| ’24 | 9.36 | 12.89 | 12.32 | 10.31 |
44.88
|
| ’23 | — | — | — | — |
48.35
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (2.79) | (0.39) | — | — |
—
|
| ’25 | (2.27) | (1.72) | 0.00 | (0.42) |
(4.41)
|
| ’24 | (1.24) | 0.11 | 2.22 | 2.78 |
3.87
|
| ’23 | (0.30) | (0.79) | — | — |
1.65
|
| ’18 | (0.47) | 1.49 | (0.47) | (0.47) |
0.07
|
| ’17 | (0.21) | (0.05) | (0.87) | (0.43) |
(1.56)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (2.82) | (0.45) | — | — |
—
|
| ’25 | (2.29) | (1.71) | (0.02) | (0.56) |
(4.57)
|
| ’24 | (1.34) | 0.09 | 2.24 | 2.70 |
3.68
|
| ’23 | (0.30) | (0.79) | — | — |
1.44
|
| ’18 | (0.47) | 1.49 | (0.47) | (0.47) |
0.07
|
| ’17 | (0.21) | (0.05) | (0.87) | (0.43) |
(1.56)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.21) | (0.11) | — | — |
—
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡ | 17.25 | 4.90 | 2.24 | 0.64 | — | — | — |
Low Price
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | 37.50 | 37.00 | 16.18 | 4.18 | — | — | — |
High Price
|
| ‡‡‡ | — | — | — | — | — | — | — | 38 | 96 | — | — | — |
Employees
|
| ‡‡‡ | — | ‡‡‡ | — | — | — | — | 0.00 | 1.18 | 0.49 | — | — | — |
Revenue/Emp
|
| — | — | ‡‡‡‡‡ | — | — | — | — | 48.35 | 44.88 | 46.88 | ‡‡‡‡‡ | — | — |
Revenue
|
| — | — | ‡‡‡‡‡ | — | — | — | — | 19.88% | 21.33% | 23.02% | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | (3.58) | (2.12) | (14.05) | — | — | — |
EBT
|
| ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | — | — | — | — | (7.41%) | (4.73%) | (29.98%) | ‡‡‡ | — | — |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | (3.82) | (2.56) | (21.23) | ‡‡‡‡‡ | — | — |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | 0.46 | 0.31 | 2.56 | — | — | — |
Depreciation
|
| ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | — | — | — | — | 306.81 | 284.75 | 8.81 | ‡‡‡‡‡ | — | — |
Revenue/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | (48.17) | (21.64) | (4.12) | ‡‡‡ | — | — |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | 10.47 | 24.54 | (0.83) | — | — | — |
Cash Flow/Sh
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | — | — | — | — | (1.32) | (1.18) | (0.03) | ‡‡‡ | — | — |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | 9.15 | 23.36 | (0.86) | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | 15.46 | (19.40) | 2.34 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | 0.16 | 0.16 | 5.32 | ‡‡‡‡‡ | — | — |
Shares
|
| — | — | ‡‡‡ | — | — | — | — | 0.00 | 0.00 | 0.00 | ‡‡‡‡ | — | — |
PE Ratio
|
| — | — | ‡‡‡ | — | — | — | — | 0.00 | 0.01 | 0.08 | ‡‡‡ | — | — |
PS Ratio
|
| — | — | ‡‡‡ | — | — | — | — | 0.00 | 0.00 | 0.31 | ‡‡‡ | — | — |
PB Ratio
|
| — | — | ‡‡‡ | — | — | — | — | 0.00 | 0.33 | 0.57 | ‡‡‡‡ | — | — |
EV/Sales
|
| — | — | ‡‡‡‡‡ | — | — | — | — | (1.29) | 3.94 | (5.85) | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | 1.65 | 3.87 | (4.41) | ‡‡‡ | — | — |
Op' Cash Flow
|
| — | — | — | — | — | — | — | (0.21) | (0.19) | (0.16) | — | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | 1.44 | 3.68 | (4.57) | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | 1.11 | 0.25 | 0.08 | — | — | — |
Working Cap'
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | 17.30 | 14.44 | 23.36 | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | 17.25 | 14.43 | 22.64 | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | 2.44 | (3.06) | 12.45 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | (21.17%) | (11.00%) | (44.49%) | — | — | — |
ROA
|
| ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | — | — | — | — | (3.99%) | (3.51%) | (19.57%) | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | — | — | — | (961.44%) | 1,769.73% | (468.45%) | — | — | — |
ROE
|
Capstone Therapeutics Corp. (CAPS), a volatile micro-cap biotech, trades at rock-bottom levels after plunging over 95% from 2024 highs, hammered by persistent losses, ballooning debt, and massive share dilution that has eroded per-share value despite recent revenue ramps to $48 million in 2023. While gross margins are improving and 2024 marked a rare positive free cash flow of $3.7 million—signaling operational scaling with revenue per employee at $1.18 million—the balance sheet remains fragile, with negative equity, net debt exceeding $14 million, and working capital slashed to a razor-thin $250,000, amplifying bankruptcy risks in this capital-hungry sector.
Analyst consensus flashes explosive 1,000% upside potential via modest 2025 revenue growth to $47 million and breakeven EBT margins, but zero insider buying and historical feast-or-famine swings tied to clinical milestones breed skepticism. Forward forecasts show dilution crushing FCF per share, with EV/Sales at a cheap 0.11x overshadowed by execution hurdles like trial failures or funding crunches.
This boom-or-bust tale underscores CAPS’s high-stakes gamble: tantalizing FCF momentum could deliver moonshot returns if deleveraging succeeds, but a revenue miss risks further halving. Dive deeper for the full dissection of fundamentals, signals, and risk-adjusted positioning.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.